C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds risk score for men

Circulation

Volumn 118, Issue 22, 2008, Pages 2243-2251

  Ridker, Paul M ^a   Paynter, Nina P ^b   Rifai, Nader ^b   Gaziano, J Michael ^b   Cook, Nancy R ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

Epidemiology; Genetics; Inflammation; Prevention; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL CLASSIFICATION; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LIFE STYLE; LIKELIHOOD FUNCTIONS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEX CHARACTERISTICS;

EID: 57749210419     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.814251     Document Type: Article

References (23)

1. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
2. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II: a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000;10:125-134.
3. Harrell FE Jr. Regression Modeling Strategies. New York, NY: Springer-Verlag; 2001.
4. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
5. D'Agostino RB, Nam BH. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. Handbook of Statistics, 23. London, United Kingdom: Elsevier; 2004.
6. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-29.
7. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
8. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008;54:17-23.
9. Pigeon JG, Heyse JF. An improved goodness of fit statistics for probability prediction models. Biom J. 1999;41:71-82.
10. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172.
11. Cook NR. Comments on "Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond" by M. J Pencina et al. Statistics in Medicine (DOI: 101002/sim.2929). Stat Med. 2008;27:191-195.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
13. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2007. ISBN 3-900051-07-0. Available at: http://www.R-project.org. Accessed August 1, 2008.
14. Grundy SM, Cleeman JI, Merz BN, Brewer H, Clark L, Hunninghake D, Pasaternak R, Smith S, Stone N; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
15. Wood D, Debacker G, Faergeman O, Graham I, Mancia G, Pyrola K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199-270.
16. McPherson R, Frolich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22:913-927.
17. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, Sacks F, Stampfer MJ. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992;86:1475-1484.
18. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of prediction models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension. 2002;39:105-110.
19. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116.
20. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Bindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136.
21. Woodward M, Brindle P, Tunstall-Pedoe H; for the SIGN Group on Risk Estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN core from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172-176.
22. D'Agostino RB Sr, Ramachandran SV, Pencina J, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
23. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:2292-2297.